Melhora clínica da dermatite atópica em crianças de 6 meses a 12 anos com o uso oral de uma associação de probióticos
Clinical improvement of atopic dermatitis in children aged 6 months to 12 years with the use of a combination of oral probiotics
Flavia Alvim Sant'Anna Addor
Resumo
Objetivos: Probióticos são organismos vivos que administrados em quantidade adequada conferem benefício ao hospedeiro.Alguns estudos demonstram que sua colonização intestinal pode influenciar a evolução de alergias sistêmicas. O objetivo do presente estudo foi avaliar clinicamente a eficácia e segurança da administração de uma associação de probióticos em crianças com dermatite atópica. Métodos: Cinquenta e seis pacientes portadores de dermatite atópica comidades entre 6 meses a 12 anos ingeriram diariamente a associação das seguintes cepas de probióticos: Lactobacillus acidophilus NCFM®,L. rhamnosus HN001®,L.paracasei Lpc-37®e Bifidobacteriumlactis HN019® em uma tomada diária, por 12 semanas, juntamente com o tratamento que vinham realizando para a dermatose. A avaliação da dermatite atópica foi realizada através do SCORAD ao início e final do estudo, além de avaliação clínica dos sinais individualmente e questionário para acessar presença de prurido e alterações do sono pela doença. Ao final do tratamento, também foi perguntado sobre o sabor e praticidade de uso da associação. Resultados: Houve melhora significante do SCORAD ao longo do tempo (p = 0,001) assim como redução dos sinais e sintomas: eritema, edema e pápulas, escoriação, liquenificação, xerose, prurido e alterações do sono. Conclusão: A associação oral dos probióticos estudados atuou de maneira significante na melhora dos sinais e sintomas de pacientes com dermatite atópica com idades entre 6 meses e 12 anos, de maneira segura e sem interferir coma terapêutica de rotina.
Palavras-chave
Abstract
Objectives: Probiotics are living organisms that confer benefit to the host when administered in adequate amounts. Some studies have shown that intestinal colonization with probiotics may influence the outcome of systemic allergies. The objective of the present study was to evaluate, based on clinical findings, the efficacy and safety of administering a specific combination of oral probiotics to children with atopic dermatitis. Methods: Fifty-six patients with atopic dermatitis aged 6 months to 12 years-old were advised to ingest once daily, for 12 weeks, along with the ongoing treatment, a combination of the following probiotic strains: Lactobacillus acidophilus NCFM®, L. rhamnosus HN001®, L. paracasei Lpc-37®, and Bifidobacterium lactis HN019. Atopic dermatitis severity was assessed using the SCORAD index, both at the beginning and at the end of the study; clinical signs were evaluated individually, anda questionnaire was used to assess pruritus and sleep disturbances caused by the disease. At the end of the treatment, patients or their guardians were also asked about the taste and convenience of the probiotic mixture. Results: There was significant improvement of SCORAD results over time (p = 0.001) as well as reduction of the following signs and symptoms: erythema, edema and papules, excoriations, lichenification, xerosis, pruritus, and sleep disturbances. Conclusion: The combination of oral probiotics significantly improved the signs and symptoms of patients with atopic dermatitis aged 6 months to 12 years. Treatment was safe and did not interfere with the routine therapy.
Keywords
Referências
1. Gigante G, Tortora A, laniro G, Ojetti V, Purchiaroni F, Campanale M, et al. Role of gut microbiota in food tolerance and allergies. Dig Dis. 2011:29(6):540-49.
2. Kummeling I, Stelma FF, Dagnelie PC, Snijders BE, Penders J, Huber M, et al. Early life exposure to antibiotics and the subsequent development of eczema, wheeze, and allergic sensitization in the first 2 years of life: the KOALA Birth Cohort Study. Pediatrics. 2007:119(1):e225-31.
3. Penders J, Thijs C, van den Brandt PA, Kummeling I, Snijders B. Stelma F, et al. Gut microbiota composition and development of atopic manifestations in infancy: the KOALA Birth Cohort Study. Gut. 2007;56(5):661-7.
4. Harmsen HJ, Wildeboer-Veloo AC, Raangs GC, Wagendorp AA, Klijn N, Bindels G,etal. Analysis of intestinal flora developmentin breastfed and formula-fed infants by using molecular identification and detection methods. J Pediatr Gastroenterol Nutr. 2000:30:61-7.
5. Food and Agriculture Organization of the United Nations (FAO). Probiotics in Food: Health and Nutritional Properties and Guidelines for Evaluation. Report of a Joint FAO/WHO Expert Consultation on Evaluation of Health and Nutritional Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria. Córdoba, Argentina, 1-4 October 2001. http://www.fao.org/3/a-a0512e.pdf
6. Perdigon G, Alaqvarez S, Nader de Marcias M, Roux ME, de Ruiz Holgado AP. Oral administration of lactic acid bacteria increase the mucosal intestinal immunity in response to enteropathogens. | Food Protect. 1990;53:404-10.
7. Famularo G, Moretti S, Marcellini S, de Simone C. Probiotics and the immune system. In: Fuller R, editor. Probiotics 2: Applications and practical aspects. 1997. p. 133-61.
8. Souza FS, Cocco RR, Sarni ROS, Mallozi MC, Solé D. Prebiotics. probiotics and symbiotics on prevention and treatment of allergic diseases. Rev Paul Pediatr. 2010;28(1):86-97.
9. Isolauri E, Arvola T, Seutas Y, Moilanen E, Salminen S. Probiotics in the management of atopic eczema. Clin Exp Allergy. 2000:30:1604-10.
10. Marschan E, Kuitunen M, Kukkonen K, Poussa T, Sarnesto A, Haahtela T, et al. Probiotics in infancy induce protective immune profiles that are characteristic for chronic low-grade inflammation. Clin Exp Allergy. 2008;38:611-8.
11. Osborn DA, Sinn JK. Probiotics in infants for prevention of allergic disease and food hypersensitivity. Cochrane Database Syst Rev. 2007:(4):CD006475.
12. Foisy M, Boyle RJ, Chalmers JR, Simpson EL, Williams HC. The prevention of eczema in infants and children: an overview of Cochrane and non-Cochrane reviews. Evid Based Child Health. 2011; 6(5):1322-39. Probióticos e dermatite atópica em crianças de 6 meses a 12 anos - Addor FA
13. Kim JY, Kwon JH, Ahn SH, Lee SI, Han YS, Choi YO, et al. Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: a double-blind, randomized, placebo-controlled trial. Pediatr Allergy Immunol. 2010 Mar;21(2 Pt 2):e386-93.
14. Severity scoring ofatopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology. 1993:186(1):23-31.
15. RoxoJr P. Atualização no tratamento da dermatite atópica. Rev Paul de Pediatr. 2006;24(4): 356-62.
16. Vaarala G. Immunological effects of probiotics with special reference to lactobacilli. Clin Exp Allergy. 2003:33:1634-40.
17. Baptista IPC, Accioly E, Padilha PC. Effect of the use of probiotics in the treatment of children with atopic dermatitis; a literature review. Nutr Hosp. 2013:28(1):16-26.
18. Morais MB, Jacob CM. The role of probiotics and prebiotics in pediatric practice. J Pediatr (Rio J). 2006;82 (5 Suppl):S189-97.
19. Strachan DP. Family size, infection and atopy: the first decade of the "hygiene hypothesis". Thorax. 2000;55 Suppl 1:S2-10.
20. Chapat L, Chemin K, Dubois B, Bourdet-Sicard R, Kaiserlian D. Lactobacillus casei reduces CD8+T-cell-mediated skin inflammation. Eur | Immunol. 2004:34:2520-8.
21. Rautava S, Kalliomaki M, Isolauri E. New therapeutic strategy for combating the increasing burden of allergic disease: probiotics - a Nutrition, Allergy, Mucosal Immunology and Intestinal Microbiota (NAMI) Research Group report. J Allergy Clin Immunol. 2005;116:31-7.
22. Rautava S, Kainonen E, Salminen S, Isolauri E. Maternal probiotic supplementation during pregnancy and breast-feeding reduces the risk of eczema in the infant J Allerg Clin Immunol. 2012:130(6):1355-60.
23. Wickens K, Stanley TV, Mitchell EA, Barthow C, Fitzharris P, Purdie G, et al. Early supplementation with Lactobacillus rhamnosus HN001 reduces eczema prevalence to 6 years: does it also reduce atopic sensitization? Clin Exp Allergy. 2013;43(9):1048-57.
24. Arunachalam K, Gill HS, Chandra RK. Enhancement of natural immune function by dietary consumption of Bifidobacterium lactis (HN019). Eur J Clin Nutr. 2000;54(3):263-7.
25. Rosenfeldt V, Benfeldt E, Nielsen SD, Michaelsen KF, Jeppesen DL, Valerius NH, et al. Effect of probiotic Lactobacillus strains in children with atopic dermatitis. J Allergy Clin Immunol. 2003:111(2):389-95.
26. Kukkonen K, Savilahti E, Haahtela T, Juntunen-Backman K, Korpela R, Poussa T, et al. Probiotics and prebiotic galactooligosaccharidesin the prevention ofallergicdiseases: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2007:119(1):192-8.
27. Foolad N, Brezinski EA, Chase EP, Armstrong AW. Effect of nutrient supplementation on atopicdermatitis in children:a systematic review of probiotics, prebiotics, formula, and fatty acids. AMA Dermatol. 2013;149(3):350-5.
28. Khailova L, Baird CH, Rush AA, McNamee EN, Wischmeyer PE Lactobacillus rhamnosus GG improves outcome in experimental Pseudomonas aeruginosa pneumonia: potential role of regulatory T cells. Shock. 2013;40(6):496-503.
29. Sawada J, Morita H, Tanaka A, Salminen S, He F, Matsuda Н. Ingestion of heat-treated Lactobacillus rhamnosus GG prevents development of atopic dermatitis in NC/Nga mice. Clin Exp Allergy. 2007:37(2):296-303.
30. Wickens K, Black P, Stanley TV, Mitchell E, Barthow C, Fitzharris P, et al. A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years. Clin Exp Allergy. 2012;42(7):1071-9.
31. Grüber C,Wendt M, SulserC, LauS, Kulig M,Wahn U, etal. Randomized, placebo-controlled trial of Lactobacillus rhamnosus GGastreatment of atopic dermatitis in infancy. Allergy. 2007:62(11):1270-6.
32. Vidal K, Benyacoub J, Moser M, Sanchez-Garcia J, Serrant P, SeguraRoggero I, et al. Effect of Lactobacillus paracasei NCC2461 on antigen-specific T-cell mediated immune responses in aged mice. Rejuvenation Res. 2008;11(5):957-64.
33. Benyacoub J, Bosco N, Blanchard C, Demont A, Philippe D, CastielHigounenc I, et al. Immune modulation property of Lactobacillus paracasei NCC2461 (ST11) strainand impactonskin defenses. Benef Microbes. 2014:5(2):129-36.
34. Guéniche A, Philippe D, Bastien P, Reuteler G, Blum S, CastielHigounenc I, et al. Randomised double-blind placebo-controlled study of the effect of Lactobacillus paracasei NCC 2461 on skin reactivity. Benef Microbes. 2014:5(2):137-45.
35. Iwabuchi N, Yonezawa S, Odamaki T, Yaeshima T, Iwatsuki K, Xiao JZ. Immunomodulating and anti-infective effects of a novel strain of Lactobacillus paracasei that strongly induces interleukin-12. FEMS Immunol Med Microbiol. 2012;66(2):230-9.
36. Valsecchi C, Marseglia A, Montagna L, Tagliacarne SC, Elli M, Licari A, et al. Evaluation of the effects of a probiotic supplementation with respect to placebo on intestinal microflora and secretory IgA production, during antibiotic therapy, in children affected by recurrent airway infections and skin symptoms.J Biol Regul Homeost Agents. 2014;28(1):117-24.
37. Salazar N, López P, Garrido P, Moran , Cabello E, Gueimonde M, et al. Immune modulating capability of two exopolysaccharideproducing Bifidobacterium strains in a Wistar rat model. Biomed Res Int. 2014:2014:106290. Braz J Allergy Immunol. -Vol. 3. N° 3, 2015 105
38. Gore C, Custovic A, Tannock GW, Munro K, Kerry G, Johnson K, et al. Treatment and secondary prevention effects of the probiotics Lactobacillus paracasei or Bifidobacterium lactis on early infant eczema: randomized controlled trial with follow-up until age 3 years. Clin Exp Allergy. 2012:42(1):112-22.
39. Torii S, Torii A, Itoh K, Urisu A, Terada A, Fujisawa T, et al. Effects of oral administration of Lactobacillus acidophilus L-92 on the symptoms and serum markers of atopic dermatitis in children. Int Arch Allergy Immunol. 2011;154(3):236-45.
40. Singh V, Kumar A, Raheja G, Anbazhagan AN, Priyamvada S, Saksena S, et al. Lactobacillus acidophilus attenuates downregulation of DRA function and expression in inflammatory models. Am J Physiol Gastrointest Liver Physiol. 2014:307(6):G623-31.
41. Karska-Wysocki B, Bazo M, Smoragiewicz W. Antibacterial activity of Lactobacillus acidophilus and Lactobacillus casei against methicillin-resistant Staphylococcus aureus (MRSA). Microbiol Res. 2010;165:674-86.
42. Borriello SP, Hammes WP, Holzapfel W, Marteau P, Schrezenmeir J, Vaara M, et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis. 2003;36:775-80.
43. Hammerman C, Bin-Nun A, Kaplan M. Safety of probiotics: comparison of two popular strains. BMJ. 2006;333(7576):1006-8.
Submetido em:
11/06/2015
Aceito em:
02/07/2016
Facebook
LinkedIn
Mendeley
StumbleUpon
Reddit
Email